Publication year: 2011 Source: Seminars in Cancer Biology, Available online 16 September 2011 Anna M. Azarova, Gargi Gautam, Rani E. George Since the original descriptions of gain-of function mutations in anaplastic lymphoma kinase (ALK), interest in the role of this receptor tyrosine kinase in neuroblastoma development and as a potential therapeutic target has escalated. As a group, the activating point mutations in full-length ALK, found in approximately 8% of all neuroblastoma tumors, are distributed evenly across different clinical stages. However, the most frequent somatic mutation, F1174L, is associated with amplification of the MYCN oncogene
Follow this link:
Emerging importance of ALK in neuroblastoma.